Atrial Fibrillation Clinical Trials

Find Atrial Fibrillation Clinical Trials Near You

Incidence of Long-TeRm Atrial Fibrillation After Acute Illness (ILR-AF)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The investigators seek to conduct a prospective study to assess the recurrence of AF in patients with acute AF using a long-term ECG monitoring strategy with an insertable cardiac monitor (ICM), which is clinically indicated in this scenario as part of the standard of care. The investigators hypothesize that patients diagnosed with acute AF in the setting of cardiac surgery will have higher rates of AF recurrence than acute AF diagnosed in the setting of non-cardiac surgery or medical illness.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient has an existing clinical indication for implantation of an insertable cardiac monitor (ICM) and will undergo ICM implantation as part of their standard medical care.

• Patient is scheduled to receive or has received a Boston Scientific LUX-DX™ insertable cardiac monitor.

• Episode of acute AF. Acute AF is defined as AF detected in an acute care setting or during an acute illness. Before enrollment, the following tests are minimally required as standard tests to establish the diagnosis of acute AF:

‣ 12-lead ECG for AF detection

⁃ 24-h ECG or telemetry monitoring for AF detection and PAC analysis

• Patient or legally authorized representative signs and dates the patient consent form.

• Patient is ≥18 years old.

• Patient is willing and able to comply with all study procedures and attend the required follow-up visits for the duration of the study.

Locations
United States
California
Sulpizio Cardiovascular Center
RECRUITING
La Jolla
Contact Information
Primary
Benjamin U Hoffman, MD, PhD
b2hoffman@health.ucsd.edu
858-246-2016
Time Frame
Start Date: 2025-11-01
Estimated Completion Date: 2027-12
Participants
Target number of participants: 100
Treatments
ILR
Related Therapeutic Areas
Sponsors
Collaborators: Boston Scientific Corporation
Leads: University of California, San Diego

This content was sourced from clinicaltrials.gov